Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Net Income (2019 - 2026)

ADC Therapeutics has reported Net Income over the past 8 years, most recently at -$33.0 million for Q1 2026.

  • Quarterly results put Net Income at -$33.0 million for Q1 2026, up 14.6% from a year ago — trailing twelve months through Mar 2026 was -$130.6 million (down 10.42% YoY), and the annual figure for FY2021 was -$223.7 million, down 12.83%.
  • Net Income reached -$33.0 million in Q1 2026 per ADCT's latest filing, up from -$41.0 million in the prior quarter.
  • Across five years, Net Income topped out at -$16223.0 in Q4 2022 and bottomed at -$66.3 million in Q2 2022.
  • Median Net Income over the past 5 years was -$44.5 million (2023), compared with a mean of -$41.8 million.
  • The largest annual shift saw Net Income skyrocketed 97.15% in 2022 before it plummeted 215.51% in 2023.
  • Over 5 years, Net Income stood at -$16223.0 in 2022, then plummeted by 279225.65% to -$45.3 million in 2023, then rose by 3.54% to -$43.7 million in 2024, then rose by 6.28% to -$41.0 million in 2025, then grew by 19.52% to -$33.0 million in 2026.
  • Business Quant data shows Net Income for ADCT at -$33.0 million in Q1 2026, -$41.0 million in Q3 2025, and -$56.6 million in Q2 2025.